DaVita

DVA Health Care Market cap $12.1B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 4, 2026

Revenue$3.55B +5% year over year

Gross profit$1.00B 28% margin

Operating profit$0.58B 16% margin

Net profit$0.27B 7% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	3.55	100%	+5%
U.S.Dialysis & related lab	3.00	84%	+4%
All other	0.55	16%	+15%
Cost of revenue	−2.55	72%
Gross profit	1.00	28% margin	+0pp
G&A	−0.42	12%	+0pp
Operating profit	0.58	16% margin	+0pp
Interest & other costs	−0.22
Tax	−0.09
Net profit	0.27	7% margin	+2pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	3.42	100%	+6%
U.S.Dialysis & related lab	2.92	86%	+4%
All other	0.49	14%	+20%
Cost of revenue	−2.33	68%
Gross profit	1.08	32% margin	+1pp
G&A	−0.42	13%	+1pp
Other	−0.18	5%	+0pp
Operating profit	0.48	14% margin	+0pp
Interest & other costs	−0.22
Tax	−0.07
Net profit	0.20	6% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.62	100%	+10%
US dialysis & related lab	3.06	84%	+6%
All other	0.56	16%	+33%
Cost of revenue	−2.59	71%
Gross profit	1.03	29% margin	−1pp
G&A	−0.47	13%	+0pp
Operating profit	0.56	16% margin	−2pp
Other income, net	0.08
Tax	−0.08
Net profit	0.57	16% margin	−2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.42	100%	+5%
U.S.Dialysis & related lab	2.97	87%	+3%
All other	0.45	13%	+21%
Cost of revenue	−2.50	73%
Gross profit	0.92	27% margin	−2pp
G&A	−0.41	12%	+0pp
Operating profit	0.51	15% margin	−2pp
Interest & other costs	−0.29
Tax	−0.07
Net profit	0.15	4% margin	−2pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.38	100%	+6%
U.S.Dialysis & related lab	2.90	86%	+2%
All other	0.48	14%	+35%
Cost of revenue	−2.43	72%
Gross profit	0.95	28% margin	+1pp
G&A	−0.41	12%	+1pp
Operating profit	0.54	16% margin	+0pp
Interest & other costs	−0.25
Tax	−0.09
Net profit	0.20	6% margin	−1pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 4, 2026 Operating margin 16% Net profit $0.27B	Apr 1 – Jun 30, 2026	Aug 4, 2026	$3.55B	+5%	16%	$0.27B	7%
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 5, 2026 Operating margin 14% Net profit $0.20B	Jan 1 – Mar 31, 2026	May 5, 2026	$3.42B	+6%	14%	$0.20B	6%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 11, 2026 Operating margin 16% Net profit $0.57B	Oct 1 – Dec 31, 2025	Feb 11, 2026	$3.62B	+10%	16%	$0.57B	16%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Oct 29, 2025 Operating margin 15% Net profit $0.15B	Jul 1 – Sep 30, 2025	Oct 29, 2025	$3.42B	+5%	15%	$0.15B	4%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 5, 2025 Operating margin 16% Net profit $0.20B	Apr 1 – Jun 30, 2025	Aug 5, 2025	$3.38B	+6%	16%	$0.20B	6%